Hayden, PJ;
Roddie, C;
Bader, P;
Basak, GW;
Bonig, H;
Bonini, C;
Chabannon, C;
... Yakoub-Agha, I; + view all
(2021)
Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
Annals of Oncology
10.1016/j.annonc.2021.12.003.
(In press).
Preview |
Text
Roddie_PIIS0923753421048766.pdf - Published Version Download (2MB) | Preview |
Abstract
BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma, and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. DESIGN: EBMT-JACIE and the European Haematology association (EHA) proposed to draft best practice recommendations based on the current literature, to support healthcare professionals in delivering consistent, high-quality care in this rapidly moving field RESULTS: Thirty-six CAR-T experts (medical; nursing; pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues. CONCLUSIONS: We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for hematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic.
| Type: | Article |
|---|---|
| Title: | Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.annonc.2021.12.003 |
| Publisher version: | https://doi.org/10.1016/j.annonc.2021.12.003 |
| Language: | English |
| Additional information: | © 2021 Published by Elsevier Ltd. This is an open access article under the CC BY 4.0 license Attribution 4.0 International (https://creativecommons.org/licenses/by/4.0/) |
| Keywords: | B-cell acute lymphoblastic leukemia (B-ALL), CAR T-cells (CAR-T), JACIE, Macrophage activation syndrome (MAS), Mantle cell lymphoma (MCL), Multiple myeloma (MM), adult relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL), cytokine release syndrome (CRS), follicular lymphoma (FL), immune effector cell-associated neurotoxicity syndrome (ICANS), long-term follow-up (LTFU) |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10141179 |
Archive Staff Only
 |
View Item |
